PCI Synthesis to Pick Up Four 2013 CMO Leadership Awards

NEWBURYPORT, MA--(Marketwired - Mar 10, 2014) - PCI Synthesis, Inc. (www.pcisynthesis.com), a Boston-based Contract Manufacturing Organization (CMO) that manufactures new chemical entities (NCE), generic active pharmaceutical ingredients (API's), and complex pharmaceutical intermediates, will pick up four Life Science Leader CMO Leadership Awards at an awards dinner to be held March 12. The four categories are Quality, Innovation, Productivity, and Reliability.

The CMO Leadership Awards are determined from a survey of more than 10,000 pharmaceutical and biopharmaceutical executives conducted on behalf of Life Science Leader magazine. The annual award recognizes those contract manufacturing organizations (CMOs) that are the most highly rated by industry respondents. The survey provides credible information to help pharmaceutical and biopharmaceutical executives vet potential partners for pharmaceutical contract manufacturing.

According to Rob Wright, Chief Editor at Life Science Leader, "Being a winner in one category is quite an accomplishment; winning in multiple categories is truly outstanding. This year, only eight companies out of more than 100 CMOs were recognized as being in the top 20 percent in four different categories."

"Winning awards across four categories is a tribute to our skilled employees, terrific clients and the recent expansions and investment in our organization and facilities," said Edward S. Price, President of PCI Synthesis.

PCI, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, currently has four chemical entities that were included in the "Top 50 Drugs in Development to Watch" list. PCI has launched more than five new proprietary APIs for the generic market with exclusive supply agreements -- bringing its total to 17 exclusive APIs in its overall pipeline.

About PCI Synthesis
PCI Synthesis is a 15-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides small and mid-sized companies with expertise needed to manufacture complex small molecules to be used in both the branded and generic market. To learn more about PCI Synthesis, its proprietary APIs, and R&D, please visit www.pcisynthesis.com.